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The treatment of extra pulmonary tuberculosis in HIV
infected patients experienced to antiretroviral therapy
raises major issues of adherence, drug interactions, side
effects and limited antiretroviral alternatives.
This is the case of a 24 year old woman from countryside,
most probably infected in 1989. She was diagnosed with
HIV infection in 2000 after repeated admissions in hospital
for pneumonia. She started ART when diagnosed with a
favorable evolution: CD4 cell count increased from 200 to
674 cells/cmm, and HIV RNA levels became undetectable.
She turned 18 in 2008 and refused to take her treatment
for almost two years. She returned to the hospital in April
2010 with a CD4 cell count of 140 cells/cmm. She started
again antiretroviral therapy with ABC+3TC+FPV/r.
In April 2013 she is admitted with night sweats, chills
and fever. At that time her CD4 cell count was 144 cells/
cmm and had 461,000 copies/mL RNA-HIV. Her chest
XR showed right pleural effusion, widened mediastinum
and the CT revealed infiltrative-like lesion at subcarinal
and retrocarinal level. Biopsy was performed and she was
diagnosed with ganglionary tuberculosis. She started
anti-TB treatment HRZE 7/7 and the ART was changed
to ABC+RAL+T20.
The anti-TB regimen is changed after three months to
rifampicin and isoniazid 7/7 because she accused arthral-
gias, tingling of the extremities, blurred vision and
decreased visual acuity. She was diagnosed with hyperuri-
cemia (pyrazinamide) and optic and peripheral neuritis
(ethambutol).
New visit at the clinic for fatigability, after 7 months of
antiretroviral therapy with ABV+RAL+T20. The CD4
cell count was 9 cells/cmm and RNA-HIV was 61,000
copies/mL. She admits taking 1 cp of Raltegravir BID, but
denies any other adherence problem. The resistance test
showed evidence of resistance to some NRTIs, to all
NNRTIs, to RAL and no resistance to PIs. The tropism
test showed that maraviroc can be used. We have excluded
relapse of tuberculosis and other diseases associated. The
ART was changed again to TDF+DRV/r+MRV and the
anti-TB treatment is change to isoniazid and moxifloxacin.
Adherence can be an important issue when treating
patients for long periods of time. Other important issues
are the drug-drug interactions (rifampicin – PIs) and the
increased side effects which may lead to loss of good
friends (Raltegravir). The poor outcome for this patient
may be due to poor HIV and tuberculosis control.
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